Three dimensional cellular microarray platform for human neural stem cell differentiation and toxicology  by Meli, Luciana et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com / l oca te / s c r
Stem Cell Research (2014) 13, 36–47Three dimensional cellular microarray platform
for human neural stem cell differentiation
and toxicology
Luciana Meli a, Hélder S.C. Barbosab,g, Anne Marie Hickeya, Leyla Gasimli c,
Gregory Nierodea, Maria Margarida Diogob,g, Robert J. Linhardt a,c,d,e,
Joaquim M.S. Cabral b,g, Jonathan S. Dordicka,c,e,f,⁎a Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY, USA
b Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, University of Lisbon, Portugal
c Department of Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute,
110 8th Street, Troy, NY 12180, USA
d Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180, USA
e Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute,
110 8th Street, Troy, NY 12180, USA
f Department of Materials Science and Engineering, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180, USA
g Department of Bioengineering, Instituto Superior Técnico, University of Lisbon, Portugal
Received 7 December 2013; received in revised form 18 March 2014; accepted 8 April 2014
Available online 18 April 2014Abstract Wedevelopeda three-dimensional (3D) cellularmicroarrayplatform for thehigh-throughput (HT) analysis of humanneural stemcell
(hNSC) growth and differentiation. The growth of an immortalized hNSC line, ReNcell VM, was evaluated on a miniaturized cell culture chip
consistingof60 nl spotsofcellsencapsulated inalginate,andcomparedtostandard2Dwellplatecultureconditions.Usinga live/deadcellviability
assay, we demonstrated that the hNSCs are able to expand on-chip, albeit with lower proliferation rates and viabilities than in conventional 2D
culture platforms. Using an in-cell, on-chip immunofluorescence assay, which provides quantitative information on cellular levels of proteins
involved inneural fate,wedemonstratedthatReNcellVMcanpreserve itsmultipotentstateduringon-chipexpansion.Moreover,differentiationof
the hNSCs into glial progeny was achieved both off- and on-chip six days after growth factor removal, accompanied by a decrease in the neural
progenitormarkers. The versatility of theplatformwas further demonstratedby complementing the cell culture chipwith a chamber systemthat
allowed us to screen for differential toxicity of small molecules to hNSCs. Using this approach, we showed differential toxicity when evaluating
three neurotoxic compounds and one antiproliferative compound, and the null effect of a non-toxic compound at relevant concentrations. Thus,
our 3D high-throughput microarray platform may help predict, in vitro, which compounds pose an increased threat to neural development and
should therefore be prioritized for further screening and evaluation.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).⁎ Corresponding author at: RensselaerPolytechnic Institute, 4005Center for Biotechnology and Interdisciplinary Studies, 110 8th Street, Troy,NY12180,USA.
E-mail address: dordick@rpi.edu (J.S. Dordick).http://dx.doi.org/10.1016/j.scr.2014.04.004
1873-5061/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
373D cellular microarray platform for human neural stem cell differentiation and toxicologyIntroduction
Neurotoxicity detection is a major challenge due to the
complexity of the central and peripheral nervous sys-
tems. The majority of commercial chemicals have not
been evaluated for developmental neurotoxicity, at least
partly due to the high cost of animal testing (National
Research Council, 2007). Regulatory agencies have tra-
ditionally used in vivo methods for adult and develop-
mental neurotoxicity testing, including neurobehavioral
evaluation of cognitive, sensory and motor functions
accompanied by neuropathological studies, with no
specific studies of the underlying cell biology (Bal-Price
et al., 2010). There is also a need to test large sets of
compounds to comply with specific regulatory require-
ments (Breier et al., 2010; Andersen and Krewski, 2009).
To this end, there is pressure to develop alternative test
strategies, which are rapid, economical, and, most critically,
highly predictive (Breier et al., 2010).
An often overlooked aspect of neurotoxicity is the impact
of chemicals, as well as drugs and drug candidates, on neural
stem cells and their terminally differentiated lineages. Stem
cells have been shown to exhibit differential sensitivities to
both non-toxic (e.g., serum) and toxic compounds, as
compared to terminally differentiated cells (Trosko and
Chang, 2010; Dietrich et al., 2006). Broad knowledge of the
toxicity of such compounds to stem cells in comparison to
other cell types in a given tissue can provide fundamental
information critical for assessing the safety of new drug
candidates and the health effects of environmental agents.
Thus, the development of new high-throughput screening
tools that enable the study of these differential effects on
stem cells and their differentiated progeny, should not only
encompass endpoints that assess chemical toxicity, but also
allow us to determine stem cell fate. This is generally
achieved by following protein markers of multipotency and
differentiation.
With this in mind, we have developed a three‐dimen-
sional (3D) cellular microarray platform for the high
throughput analysis of hNSC differentiation and toxicity
screening (Fig. S1). Our system has the ability to expand
our knowledge of neurotoxicity by discriminating between
toxic and nontoxic compounds. It can also detect differen-
tiation stage-specific toxicities. Knowledge of differences
in molecular toxicity to stem cells in comparison to other
cell types is critical for assessing safety of new drug
candidates and health effects of environmental agents
(Laustriat et al., 2010). We demonstrated herein the
differentiation of the ReNcell VM hNSC line into glial
progeny on a 3D cellular microarray platform. This platform
was then used to screen dose-dependent toxicity of a
number of neurotoxic compounds, leading to identification
of compounds with differential toxicity to hNSCs in relation
to the differentiated glial progeny.
Materials and methods
Cell culture
ReNcell VM (Millipore) is an immortalized neural progenitor
cell line derived from the ventral mesencephalon region of a10-week human fetal brain. All cells used in this investiga-
tion were from passage 31 or lower; previous work (Donato
et al., 2007) has shown that these cells maintain a stable
karyotype past 45 passages. Cells were cultured according to
the manufacturer's instructions. Briefly, the ReNcell VM cells
were expanded in expansion medium (ReNcell NSC Mainte-
nance Medium (Millipore) supplemented with 20 ng/ml of
epidermal growth factor (EGF, Millipore) and 20 ng/ml of
basic fibroblast growth factor (bFGF, Millipore)) on laminin-
coated (1.7 μg/cm2) TC-treated culture flasks at 37 °C in a
5% CO2 humidifier incubator. The medium was renewed
every two days during proliferation, and the cells subcultured
approximately every five days (90% confluence) by detaching
them with Accutase® (Millipore). After each passage, cell
concentration and viability were determined by counting with
a hemocytometer (Hauser Scientific) using the trypan blue dye
(Invitrogen) exclusion test, and the cells were once again
seeded at 5 × 104 cells/ml in freshly coated flasks. Differen-
tiation of the cells was accomplished by adding fresh
differentiation medium (ReNcell NSC Maintenance Medium
without growth factors) to confluent monolayers of cells.
Unless otherwise indicated, cells were incubated for 6 days in
differentiation medium, replenishing the medium every
2 days.Preparation of 3D microarray cultures
ReNcell VM cells were cultured in three-dimensional (3D)
microarrays by embedding them in alginate, and printing
the gel mixture in 60 nl spots on hydrophobic glass slides.
Briefly, a poly-L-lysine (PLL)–BaCl2 mixture was made by
mixing a sterile 0.1 M BaCl2 solution in deionized water
with a 0.01% (w/v) sterile PLL solution (Sigma) in a 1:2
volume ratio. The PLL–Ba2+ mixture was spotted onto
poly(styrene-co-maleic anhydride) (PSMA) coated glass
slides using a MicrosSys 5100-4SQ microcontact microarray
spotter (Genomics Solutions), making a 6 × 8 × 8 patterned
array of 60 nl spots on the chip and allowing them to dry.
Each spot had a diameter of ca. 600 μm and a height of ca.
70 μm. A ReNcell VM cell suspension in media was then
mixed with a low viscosity alginic acid (Sigma) solution in
deionized sterile water such that the final alginate
concentration was 1% (w/v), and the concentration of
cells in suspension was 5 × 106 cells/ml, unless otherwise
indicated. Subsequently, the cell-alginate mixture was
printed (60 nl/spot, 300 cells/spot) on top of the dried
PLL–Ba2+ spots, which allowed the nearly instantaneous
gelation of the alginate matrix. During the printing process,
the humidity in the microarray chamber was maintained
above 90% to prevent water evaporation of the spots.
Following printing, the slide was fitted with a commercially
available 8-well polystyrene medium chamber coated with
a biocompatible adhesive (Lab-Tek II, Nunc) that allowed
firm attachment of the chip to the chamber, and physically
separated groups of spots within the slide. Each of the
wells, containing 48 cell culture microarray spots, was
filled with 250 μl of ReNcell expansion medium. Following
expansion, differentiation, exposure to drugs and/or
assaying the chambers could be easily removed with a
slide separator.
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Cell viability on the 3D microarrays was assessed via a Live/
Dead® viability/cytotoxicity kit for mammalian cells
(Invitrogen). The slides were separated from the chamber,
and subsequently rinsed twice with a wash solution (140 mM
NaCl (Sigma-Aldrich) and 20 mM CaCl2 (Sigma) at pH 7).
Then, they were immersed in a 0.5 μM calcein AM/1 μM
ethidium homodimer 1 solution to detect viable and dead
cells via green and red fluorescence, respectively. After
45 min incubation at room temperature, the dyes were
removed and the chips rinsed thoroughly with the wash
solution and then dried. The slides were scanned with a
GenePix 4200A scanner (Molecular Devices) using a 488 nm
laser for excitation, with a standard blue filter and a
645AF75/594 filter for detection of the green and red dyes,
respectively. The fluorescence intensity from the resulting
image was quantified with the GenePix Pro 6.0 software
(Molecular Devices).
To quantify viability in 2D cultures within 96-well microti-
ter plates we used the methylthiazolyldiphenyl-tetrazolium
bromide (MTT) assay. Cells seeded at a density of 5000 cells/
well were allowed to attach for at least 5 h. To assay the cells,
50 μl of a 2.5 mg/ml MTT (Sigma) reagent solution prepared in
sterile conditions was added to each well, and incubated for
3 h under culture conditions. The culture supernatant was
subsequently removed and the formazan crystals generated in
metabolically active cells were dissolved with 150 μl of
dimethylsulfoxide (DMSO, Sigma-Aldrich). The absorbance
was read using a SpectraMax M5 Multi-Mode Microplate Reader
(Molecular Devices) at 590 nm with a reference filter at
690 nm.Western blotting analysis of marker proteins
ReNcell VM cells were seeded and expanded or differentiated
on a T-75 flask as described above. After detachment of nearly
confluent monolayers of differentiated or non-differentiated
cells, whole-cell extracts were prepared by lysing the cells with
NP40 lysis buffer (Boston BioProducts) supplemented with a
protease/phosphatase inhibitor cocktail (Cell Signaling Tech-
nology). The lysates were collected and the protein content
was estimated using a BCA assay (Thermo Scientific Pierce),
allowing equal amounts of protein to be loaded in each lane.
The samples were resolved in 4–20% precast SDS-PAGE gradient
gels (Precise™ Protein Gels, Thermo Scientific) for 30 min at
150 V and electrotransferred to a nitrocellulose membrane
(Bio-Rad). For the transfer, the gel was first equilibrated for
1 h in the transfer buffer (Bio-Rad), and then transferred to the
membrane for 60 min at 100 V and 4 °C. The membrane was
subsequently immersed in blocking buffer (5% (w/v) skim milk
and 0.05% (v/v) Tween-20 in phosphate-buffered saline (PBS))
for 1 h at room temperature.
The primary antibody solutions were then prepared in the
blocking buffer and incubated with the membrane for 1 h at
room temperature. The antibodies used were mouse mono-
clonal anti-GalC (1:300 dilution, EMD Millipore), mouse
monoclonal anti-GAPDH (1:3000 dilution, Abcam), mouse
monoclonal anti-GFAP (1:1500 dilution, Abcam),mousemono-
clonal anti-Nestin (1:500 dilution, BD BioScience), mouse
monoclonal anti-βIII-Tubulin (1:1000 dilution, Covance), andrabbit polyclonal anti-γ-Tubulin (1:1000 dilution, Sigma-
Aldrich). Following primary antibody incubation, the mem-
brane was washed thoroughly with 0.05% (v/v) Tween-20 in
PBS (PBS-T) and incubated with the peroxidase-conjugated
goat anti-mouse or goat anti-rabbit IgG secondary antibody
(1:1000 dilution, Invitrogen) in blocking buffer for 1 h at room
temperature. Themembranewas once again washed thoroughly
with PBS-T and immunoreactivity was visualized using a
chemiluminescence reagent (SuperSignal, Pierce).On-chip, in-cell immunofluorescence assay
Cellular immunofluorescence assays were performed on
both non-differentiated ReNcell VM cells (+EGF, +FGF-2)
and differentiated cells (−EGF, −FGF-2) cultured both in the
3D microarrays (on-chip) and in conventional 2D culture
flasks (off-chip), for which the cells were printed immedi-
ately before assaying. Non-differentiated cells (on-chip)
were printed and incubated for 6 days in expansion medium
to permit their expansion in microarray cultures, while the
cells in the flask (off-chip) were expanded to 90% conflu-
ence, detached, and subsequently printed. Differentiated
cells (on-chip) were printed, allowed to expand for 3 days in
expansion medium and subsequently incubated in differen-
tiation medium for 6 days. For off-chip differentiation, cells
seeded in flasks were expanded to 90% confluence and were
then switched to differentiation medium for 6 more days,
after which they were printed and assayed.
Following expansion or differentiation, the chips were
rinsed three times with a wash buffer (Tris-buffered saline
(TBS) containing 10 mM of CaCl2) and subsequently fixed with
a 3.7% (v/v) formaldehyde (Sigma) solution in the washing
buffer for 20 min. The cells were then permeabilized for
10 min with 0.15% (v/v) Triton X-100 (Sigma), rinsed three
times with the wash buffer, and incubated overnight at 4 °C
with a blocking solution (TBS Superblock from Pierce). After
blocking, the chips were rinsed three times with wash buffer
containing 0.1% (v/v) Tween-20 (MP Biomedicals) and incu-
bated for 2 h at room temperature with the various primary
antibodies diluted in 1% (w/v) bovine serum albumin (BSA,
Santa Cruz Biotechnology) in the wash buffer. The antibodies
used were rabbit polyclonal anti-GalC (1:250 dilution, Santa
Cruz Biotechnology), mouse monoclonal anti-GAPDH (1:100
dilution, Abcam), mouse monoclonal anti-GFAP (1:100 dilu-
tion, Abcam), mouse monoclonal anti-Nestin (1:100 dilution,
BD BioScience), mouse monoclonal anti-βIII-Tubulin (1:400
dilution, Covance), rabbit polyclonal anti-γ-Tubulin (1:1000
dilution, Sigma-Aldrich), rabbit polyclonal anti-SOX2 (1:100,
Abcam), and rabbit monoclonal anti-COX IV (1:125, Cell
Signalling). After washing the cells thoroughly, the
peroxidase-conjugated goat anti-mouse or goat anti-rabbit
IgG secondary antibody (1:1000 dilution, Invitrogen) was
added, and the cells were incubated at room temperature
for 1.5 h. A tyramide signal amplification kit (Invitrogen) was
subsequently used following themanufacturer's instructions to
detect the presence of the target proteins through fluores-
cence analysis. The microarrays were scanned with a slide
scanner as described above (at 488 nm with a standard blue
laser). The experiment was repeated at least three times,
with 48 replicates per marker probed in each chip. The
fluorescence signal from GAPDH was used as internal control,
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and tyramide dye alone was used as a negative control. Similar
results were obtained when using anti-γ-Tubulin to normalize
the fluorescence signals.
Immunocytochemistry
Following growth and/or differentiation on laminin-coated
35-mm glass-bottom cell culture dishes (Greiner Bio-One),
the medium was removed and the cells were washed twice
with PBS. The cells were fixed with a cold 3.7% (v/v)
formaldehyde (Sigma) solution in PBS for 10 min, and then
washed three times with PBS. Cells were then permeabilized
with PBS containing 0.1% Triton-X100 at room temperature
and washed three times with PBS. The cells were blocked in
PBS containing 1% BSA for 20 min at room temperature.
Alexa Fluor 488 phalloidin (1:40 dilution, Life Technologies)
in blocking solution was used to detect filamentous actin
(F-actin); cells were incubated for 20 min in the dark at
room temperature, then washed three times with PBS,
counterstained with 10 μg/ml Hoechst 33342 (Sigma) for
1 min, in the dark, and washed once with PBS. To preserve
fluorescence, all samples were coated with Prolong Gold
Antifade Reagent (Life Technologies).
Cytotoxicity of test compounds in ReNcell VM cell
line and derived differentiated cells
To probe differential cytotoxicity in ReNcell VM cells and
their differentiated progeny, we examined the effect on cell
viability of three known developmental neurotoxicants:
retinoic acid (Adams and Lammer, 1991), cadmium chloride
hydrate (Costa et al., 2007), and dexamethasone (Baud,
2004). In addition to these compounds, we also tested the
effect of 5-fluorouracil and acetaminophen on cytotoxicity.
The former is a known antiproliferative compound (Bogdahn
et al., 1987; Longley et al., 2003), while the latter is an
analgesic approved for use during pregnancy and presumed
to have no effect on the developing central nervous system
(Buzanska et al., 2009; Saunders et al., 1980). All com-
pounds were purchased from Sigma, and were dissolved in
DMSO (Sigma) to prepare stock solutions, which were stored
in frozen aliquots. Immediately before use, the stocks were
diluted in media to a concentration corresponding to the
highest dose tested for each compound. The remaining doses
were prepared by 4-fold serial dilutions of the highest dose.
A vehicle concentration of 0.5% DMSO was used in all doses
for the five compounds.
For determination of non-differentiated ReNcell VM
cytotoxicity, cells were printed in the 3D microarrays and
incubated for 3 days in expansion medium, after which the
media was removed and the cells incubated in expansion
medium containing varying doses of each drug. In the case of
the differentiated cells, the printed 3D microarrays were
similarly incubated for 3 days in expansion medium, subse-
quently cultured in differentiation medium for 6 more days,
and finally incubated in differentiation medium containing
the drug solutions. Following a 24 h incubation period with
the compounds, the drug solutions were removed and the
cells were cultured with either expansion or differentiation
media for an additional 48 h. Cytotoxicity was determinedvia a live/dead cell viability assay, as described previously.
Cells incubated in media with 0.5% DMSO served as our
positive “live cell” control, and cells treated with 5% saponin
for 30 min served as the negative “dead cell” control. To
produce the conventional dose–response curve, green
fluorescence intensity values (calcein AM signal) were
normalized with these controls and plotted against the
logarithm of the tested concentrations. The IC50 values were
obtained by fitting the data to a sigmoidal dose–response
curve (variable slope) using Prism 4 (GraphPad Software).
Each experiment was repeated at least three times, having
48 replicates per concentration of each chemical.
Statistical analysis
Changes in marker expression and chemosensitivity upon
differentiation were determined using a one-way analysis of
variance (ANOVA) followed by planned comparisons using
Student's t test. For all comparisons, results were considered
significant if p b 0.05. Data are represented graphically as
the mean ± SEM.
Results and discussion
Proliferation of ReNcell VM cell line in 2D monolayers
and 3D microarrays
The influence of the 3D alginate environment on cell
proliferation was first investigated by comparing cell growth
on-chip to that in 2D cultures. The on-chip growth was
performed as described by Meli et al. (2012) and shown in
Fig. S1. The expansion of the hNSC ReNcell VM cell line was
assessed in conventional 2D cultures using an MTT assay to
detect metabolically active cells in a 96-well microtiter
plate. The cells expanded readily in monolayer culture, with
doubling times of 22 h in the exponential phase of growth
(Fig. 1A). The growth of ReNcell VM cells embedded in the
3D microarrays, and monitored using a live/dead cell
viability assay, however, shows a striking 4-day lag period.
This is followed by growth at much slower rate than in 2D
culture, with doubling times of 84 h (Fig. 1A).
Changes in cell viability in the 3D microarrays were
gauged indirectly by following the ratio of average
red-to-green fluorescence intensity with time, normalized
to time zero, as seen in the inset of Fig. 1A (proportional to
dead-to-live cell ratio). These data indicate that cell
viability immediately after printing is ca. 50%. The viability
then decreases during the lag phase of the growth curve,
which is followed by a recovery to initial viability once cell
death ceases.
Previous studies have shown similar sharp decreases in
the viability of human embryonic stem cells (hESCs)
embedded in alginate microcapsules of roughly 500 μm in
diameter, i.e., 3-orders of magnitude larger than our
microarray spots (Chayosumrit et al., 2010). Specifically,
the ability of the hESCs to maintain viability, proliferate and
form clusters depended on the concentration and type of
divalent cation used to form the alginate matrix (e.g.,
calcium or barium). These parameters are thought to affect
viability by altering the permeability of the matrix to
nutrients and growth factors. Additionally, the proliferation
Figure 1 Comparison of ReNcell VM cell expansion in the 3D cellular microarray platform with expansion in conventional 2D culture
platforms. (A) Cells seeded at 160 cells/mm2 in a 96-well microtiter plate (5000 cells/well; 2.5 × 104 cells/ml medium) grow
exponentially with doubling times of 22 h, and no lag phase observed (open circles, right axis). Cells seeded in microcultures in
alginate spots at 5000 cells/mm3 (5.8 × 104 cells/ml medium) demonstrate a 4-day lag, followed by a growth phase with slower
proliferation (tD = 84 h) (open squares, left axis). The inset shows the changes in ReNcell VM viability during 3D culture, measured
indirectly by following the ratio of average red-to-green fluorescence intensity with time, normalized to the first measurement taken
after printing (typically 4 h after cell detachment). The data indicate a decrease in viability during the lag phase. Data represent the
mean ± SEM. (B) Bright field images of the alginate microcultures (300 cells/spot; 5 × 106 cells/ml) after cell expansion on-chip using
expansion medium (left panel), and cells similarly expanded and subsequently differentiated for 6 days in differentiation medium
(right panel). ND refers to non-differentiated cells, DIFF refers to differentiated cells.
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chemistry of the 3D milieu and culture dimensionality. For
example, Kisaalita and co-workers (Cheng et al., 2008; Wang
and Kisaalita, 2010) showed that neural progenitor cells
(NPCs) cultured in 3D polystyrene scaffolds in 96-well plate
assays grew as clusters with lower neurite density and
shorter length than observed in 2D cultures, and also grew
more slowly (approx. 50% of that in 2D). Additionally, Ashton
et al. (2007) suggested that the growth rate of NPCs in analginate hydrogel was slowed due to the small pore size.
Regardless of the cause of decreased initial hNSC viability in
the alginate-based microarrays, the cells undergoing expan-
sion in the 3D microarrays do show formation of cell clusters.
These clusters are seen in the bright field image of ReNcell
VM cells encapsulated in an alginate microarray spot and
cultured in expansion medium for 6 days (left-hand side of
Fig. 1B). The figure also contains an image of a ReNcell
microculture where the cells have been expanded and
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Fig. 1B). In this case, cell clusters are seldom observed.Validation of in-cell, on-chip microarray immuno-
fluorescence assay for studying ReNcell VM fateTo quantify the levels of specific marker proteins that could
help us determine the state of differentiation of the cells,
we employed an in-cell, on-chip immunofluorescence meth-
odology, similar to that used previously for mouse ESCs and
several human carcinoma cell lines (Fernandes et al., 2009;
Fernandes et al., 2008; Meli et al., 2012). As a validation of
our cell-based assay, we first studied assay sensitivity and
range for several marker proteins after printing the non-
differentiated ReNcell VM hNSCs. We observed an increase in
the fluorescence intensity of the SOX2 neural stem cell marker
and the GAPDH internal control marker with increasing number
of non-differentiated cells printed per spot (Fig. S2A). The
number of cells per spot correlated linearly with the green
fluorescence intensity for both markers over a range of cell
densities (0–400 cells/spot) (Fig. S2B).
Similar results were obtained for the hNSCs subjected to a
standard monolayer differentiation protocol for 6 days prior
to microarray printing using Nestin (hNSC) and GFAP (astro-
cyte) markers, as well as GAPDH (Fig. S2C). It is important to
note that when the marker signals are normalized to the
internal control, GAPDH, the response is essentially constant
regardless of the cell number (Fig. S2D). It is also important to
note that the extent of nonspecific binding of the secondary
antibody was evaluated by reproducing the immunofluores-
cence protocol, but omitting addition of a primary antibody.
The weak response obtained was used to define background
levels that were subtracted from the marker signal of interest
prior to normalization with the internal control.
We then proceeded to use the in-cell, on-chip immunoflu-
orescence assay to compare the levels of several neuro-
developmental stage-specific markers in hNSCs cultured on
laminin-coated flasks in their proliferative non-differentiated
state, to those in cells differentiated by removal of growth
factors for 6 days. This relatively short induction process
yielded striking differences in themorphological characteristics
of the cells, which transition from a cobblestone morphology
when confluent, to more rounded bodies with extensive
outgrowths (Fig. 2A). These morphological changes were
highlighted by staining the cells with Alexa Fluor 488 conjugated
phalloidin (Fig. 2E).
The ReNcell VM cell line has been shown to stain positive
for the neural stem cell marker, Nestin, in its non-
differentiated state (Donato et al., 2007). This was indeed
the case for our cells, which show a relatively weak but
distinct Nestin signal (normalized to GAPDH) in their prolifer-
ative state immediately after printing the cells onto the
microarray (Fig. 2C and D). This signal is lost (p b 0.05) in cells
that are not supplemented with growth factors, suggesting
that the decrease in this multipotency marker is a sign of cell
differentiation. As a reference, we compared ourmethod with
standard Western blotting (Fig. 2B). The cells show a strong
band corresponding to Nestin when expanded in the presence
of growth factors, whereas in the absence of growth factors
the band disappears.Concomitant with the decrease in Nestin, we observe a
sharp increase in the levels of the GFAP glial marker, both in
Western analysis and via in-cell, on-chip immunofluores-
cence. This increase signals astrocytic commitment of the
ReNcell VM progeny after applying the monolayer differen-
tiation protocol. Interestingly, ReNcell VM is GFAP+ even
prior to mitogen withdrawal, while still exhibiting neural
progenitor cell characteristics and expressing Nestin. Similar
marker profiles have been reported during the early stages
of neural commitment of stem cells (Rieske et al., 2007;
Buzanska et al., 2009). For example, Rieske et al. (2007)
demonstrated that a population of GFAP+ cells derived from
fetal human brain parenchyma express both Nestin and
βIII-Tubulin in their initial proliferative phase, and can later
generate two distinct progenies, one of which is of glial
lineage with up-regulated GFAP expression and down-
regulated Nestin and βIII-Tubulin expression. Indeed, the
expression of the neuronal marker βIII-Tubulin is evident in
ReNcell VM prior to differentiation (Fig. 2), when the cells
are still supplemented with growth factors. The signal
decreases substantially as the cells commit to a glial lineage.
In this regard, it should be noted that in the case of
hESC-derived neural progenitors, it has been suggested by
Krencik et al. (2011) that progenitors first give rise to
neurons and then to astrocytes. While this may seem to
indicate that this procedure is limited to glial differentiation,
Donato et al. (2007), working with the same cell line, showed
that it is possible to generate mainly neurons by altering the
differentiation process to include a pre-aggregation step in
the differentiation process.
The hNSCs cultured under both expansion and differentiation
conditions appear to express low levels of the oligodendrocyte
marker GalC. Western blot results suggest very little change of
GalC upon differentiation, while in-cell, on-chip immunofluo-
rescence indicates a small, but statistically significant, decrease
in GalC expression. However, as shown in Fig. 2C, the anti-GalC
primary antibody used causes significantly more nonspecific
binding than the other antibodies, particularly in the film
surrounding the alginate spots, and actually leads to negative
values of the signal after differentiation when subtracting the
background (secondary-only control) from the primary signal
(Fig. 2D). It should be noted that the choice of antibodies for the
in-cell, on-chip immunofluorescence assays is critical, especially
with regard to non-specific binding, which can result in
significant levels of background fluorescence, as can be seen
with GalC (Figs. 2C and 3A). This increased background may
impact in-cell data, affecting its ability to correlate quantita-
tively with Western data.
Once we had demonstrated the concordance between the
in-cell, on-chip immunofluorescence assay and Western
blotting, we endeavored to assess stem cell fate on-chip. To
that end, we sought to evaluate how established marker
profiles might change when the cells were cultured on-chip
with or without growth factor supplementation. Cells were
allowed to overcome the lag phase of growth observed in the
microarrays by expanding them for 6 days on-chip before
assaying. In the case of the differentiated cells, they were
cultured on-chip for 3 days in expansion medium before
inducing differentiation for an additional 6 days, and subse-
quently assayed. Qualitatively similar marker profiles are
observed in the proliferative and differentiated cell popula-
tions cultured on-chip (Fig. 3) as those observedwhen the cells
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immediately before assaying (Fig. 2C and D). Specifically, we
observe a decrease in Nestin and βIII-Tubulin expression and a
large increase in GFAP expression upon differentiation,
suggesting once again the generation of a cell population
primarily composed of cells differentiated towards astrocytic
phenotype after induction. Interestingly, on-chip expansion
appears to lead to higher βIII-Tubulin and GalC signals than
cells proliferating off-chip. The decrease in expression of the
neuronal marker upon differentiation is less abrupt in the 3D
microarrays than in conventional cultures, whereas the GalC
signal drops off to zero, in both cases.
The marker profile results depicted in Figs. 2D and 3B do
not change substantially when using γ-Tubulin to normalize
the marker signals (results not shown), indicating that
GAPDH serves as an adequate control for the ReNcell VM
cells and their progeny. This is further illustrated in Fig. S3,
where we show the evolution of Nestin and GFAP expression
during expansion and differentiation, using three different
internal controls to normalize the signals, GAPDH, γ-Tubulin,
and COXIV, all showing similar trends.
It is also important to note that the viability of cells
cultured on-chip tends to be lower than that of their
off-chip counterparts, particularly in the case of differen-
tiated cells, where a 3-fold increase in red-to-green
fluorescence intensity is observed (results not shown).
Besides the lag phase in growth and the slower proliferation
rates observed on-chip, this is also likely a result of the
entrapment of dead cells within the alginate matrix. For
the off-chip cultures, detached dead cells are regularly
removed as the medium is replenished, whereas on-chip
these cells are entrapped in the 3D network until they
degrade. This is of particular importance during differen-
tiation, where we observed significant cell death and no
proliferation. In addition to modifying the matrix chemistry
and permeability, the incorporation of survival factors, like
GDNF and BDNF, in the differentiation medium could help
address the low viability observed (Miljan, 2007).Differential effect of test compounds on cytotoxicity
of ReNcell VM and differentiated progeny
There is a rapidly emerging need to develop in vitro, high-
throughput screens to assess neurotoxicity of drugs andFigure 2 Cell-based microarray immunofluorescence assay for qua
platforms. (A) Bright field microscopy images of ReNcell VM cells
expansion medium, and cells similarly expanded and subsequently d
ND indicates non-differentiated cells; DIFF indicates differentiate
commitment after 6 days of differentiation, as evidenced by the de
signal (γ-Tubulin and GAPDH were used as loading control). (C) On-c
cells expanded or differentiated in 2D culture platforms (off-chi
(5 × 106 cells/ml). Each spot has a diameter of 600 μm, as indicat
signal obtained from microarrays such as those illustrated in panel C
γ-Tubulin normalization). Statistically significant differences
non-differentiated cells are represented with (*) for p b 0.05. Data
48 replicate microcultures. (E) Expression of F-actin (green) by ReNc
using expansion medium, and cells similarly expanded and subsequ
panel). Cell nuclei were counterstained with Hoechst 33342 (
differentiated cells. Scale bars: 20 μm.chemicals at different stages of neural development. Cell-
based models that mimic the in vivo environment are ideal
to predict the differential response of various populations of
cells in the brain to a given compound, at different stages of
development.
In this context, we wanted to assess whether our cell-
based platform could be used to probe in vitro cytotoxicity
of a population of hNSCs and its differentiated progeny in a
high throughput manner, when challenged with five model
compounds. We chose three developmental neurotoxicants
(cadmium chloride, retinoic acid and dexamethasone), an
antiproliferative anti-cancer agent (5-fluorouracil), and a
compound that should have no effect on the developing
central nervous system (acetaminophen).
As before, the printed cells were allowed to overcome
the lag phase of growth and, in the case of the cells
differentiated towards an astrocytic phenotype, differenti-
ated for 6 days before being challenged with the compounds
for a period of 24 h. This was followed by an additional
incubation with either expansion or differentiation medium
for 2 days, before determining cytotoxicity via a live/dead
cell viability assay. MTT analysis indicated that the DMSO at
the concentration used in these analyses (0.5%) was not
toxic, yielding cell viability of 100.8 ± 4.6%, compared with
cells grown in the absence of DMSO, which had a cell viability
of 100.0 ± 11.3%.
The dose–response curves of the five compounds for both
populations of cells are depicted in Fig. 4 and a summary of
IC50 values are given in Table 1. No statistically significant
difference was observed between the log IC50 values of the
two cell populations for retinoic acid, cadmium chloride,
and 5-fluorouracil, with the latter two being the most toxic
chemicals overall. The effect of retinoic acid and cadmium
chloride on hNSCs, as measured by the IC50 values, is
consistent with the results of Breier et al. (2008) who
studied the closely related ReNcell CX neural progenitor cell
line (non-differentiated) in 2D well plate experiments. On
the other hand, these authors reported that 5-fluorouracil
inhibited proliferation without affecting viability after 24 h
of incubation with the drug. The difference may be related
to the fact that in our experimental protocol the cells are
incubated in medium for 2 days after being challenged with
the compounds for 24 h, and the dose responses are
quantified in terms of the percentage of live cells (relative
to the growth of the cells in the absence of the chemicals).ntification of marker proteins in ReNcell VM cells cultured on 2D
expanded in monolayer culture for 3 days (upper panel) using
ifferentiated for 6 days in differentiation medium (lower panel).
d cells. (B) Western blot analysis showing astrocytic lineage
crease in Nestin expression, and concomitant increase in GFAP
hip immunofluorescence assay of marker proteins in ReNcell VM
p) and subsequently printed for analysis with 300 cells/spot
ed. (D) Quantification of the normalized fluorescence intensity
, using GAPDH as internal control (similar results obtained with
between the normalized intensity of differentiated and
represent the mean ± SEM, with n ≥ 3 experiments, each with
ell VM cells expanded in monolayer culture for 3 days (left panel)
ently differentiated for 6 days in differentiation medium (right
blue). ND indicates non-differentiated cells; DIFF indicates
433D cellular microarray platform for human neural stem cell differentiation and toxicologyThus, our cytotoxicity assays involve both inhibition of cell
proliferation and decrease in cell viability. Importantly, the
IC50 values of 5-fluorouracil, extracted from the dose
response curves of the ReNcell VM and its astrocytic
derivatives (8.4 and 5.2 μM, respectively), coincide well
with literature values for various cancer cell lines (IC50 =
1–85 μM) (Chauffert and Dimanche-Boitrel, 1998; Lee et al.,
2008; Meli et al., 2012). Finally, we compared dexametha-
sone and acetaminophen in 2D ReNcell VM cultures in a
96-well plate format. The IC50 values were 215 and 1760 μM,
respectively. These numbers are lower than that obtained in3D (Table 1), which is largely consistent with our previous
studies comparing 2D and 3D for cytotoxicity (Lee et al.,
2008).
Proliferating ReNcell VM cells challenged with high concen-
trations of acetaminophen (0.02–20 mM) show greater suscep-
tibility to this analgesic than the cells differentiated towards
an astrocytic phenotype (IC50 values are 2.4 and 14.1 mM,
respectively). Both of these concentrations, however, are
higher than the toxic blood concentrations required to cause
hepatotoxic effects (~0.2–1 mM) (Clemedson et al., 2007). As
expected, the viability of the cells below the hepatotoxic range
Figure 4 Comparison of the dose response of ReNcell VM cells and their differentiated progeny (following 6 days of growth factor
removal) to 3 developmental neurotoxicants (retinoic acid-(A), cadmium chloride-(B) and dexamethasone-(C)), and a
non-neurotoxicant (acetaminophen-(E)). Cytotoxicity was determined with a live/dead cell viability assay and the data were fitted
to a sigmoidal dose response to obtain the IC50 values. The figures show representative curves where each data point is the mean of 48
replicates ± SEM.
Figure 3 On-chip, in-cell immunofluorescence assay for quantification of marker proteins in ReNcell VM cells cultured in the 3D
microarray platform. (A) Scanning images of portions of the microcultures containing ReNcell VM cells (seeded at 300 cells/spot) after
expansion or differentiation on-chip, followed by immunoassay of marker proteins. (B) Quantification of marker protein expression in
differentiated and non-differentiated cells through analysis of the normalized fluorescence intensity signal obtained from the
scanning microarray images using GAPDH as the internal control. Statistically significant differences between the normalized
intensity of differentiated and non-differentiated cells are represented with (*) for p b 0.05. Data represent the mean ± SEM, with
n ≥ 3 experiments, each with 48 replicate microcultures.
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Table 1 Response of ReNcell VM cells and their differentiated progeny to various compounds, as measured by their IC50 values.
Compound Non-differentiated Differentiated
log (IC50 μM) IC50 (μM) log (IC50 μM) IC50 (μM)
5-Fluorouracil 0.92 ± 0.23 8.40 0.70 ± 0.06 5.20
CdCl 0.87 ± 0.49 7.36 0.98 ± 0.04 10.2
Dexamethasone* 3.11 ± .09 1920 1.60 ± 0.09 58.5
Retinoic acid 1.18 ± 0.38 15.6 1.00 ± 0.81 10.4
Acetaminophen* 3.38 ± 0.02 2450 4.11 ± 0.08 14,100
Statistically significant changes in log IC50 values after differentiation were observed for dexamethasone and acetaminophen (p b 0.05,
represented with (*)). The data represents the mean ± SEM, with n = 3 experiments, where each concentration had 48 replicate
microcultures.
453D cellular microarray platform for human neural stem cell differentiation and toxicologyof concentrations remains unaffected for both the hNSC line and
its progeny, and is consistent with reports in the literature
(Breier et al., 2008; Buzanska et al., 2009). Additionally,
acetaminophen has previously been shown to be non-toxic to a
hepatoma cell line (Hep3B), when P450 metabolism was absent
(Lee et al., 2008).
Interestingly, the differentiated cells were more sensitive
to dexamethasone than the hNSC population. Specifically,
there is a marked differentiation-specific toxicity to dexa-
methasone, where the IC50 value of the differentiated cells is
two orders of magnitude lower than that of the hNSCs
(0.06 mM to 2 mM, respectively). The relatively high
chemoresistance of the hNSCs observed is consistent with
the negligible effect on viability and limited impact on
proliferation seen by Brier and coworkers for the ReNcell CX
cell line challenged with concentrations of dexamethasone of
up to 100 μM (Breier et al., 2008).
The panel of compounds chosen for testing helps illustrates
the capabilities of our ReNcell VM-based microarray platform
for neurotoxicity screening. Our results demonstrate the ability
of the 3D cellular microarray system to discriminate between
toxic and non-toxic compounds. This is evidenced by the low
toxicity shown by the microarray cultures to acetaminophen
(extremely high IC50 values). In contrast, the response to the
antiproliferative and neurotoxic compounds tested seems to be
consistent overall with published data on hNSC lines, thus
demonstrating adequate sensitivity to detect adverse effects
of target compounds (Breier et al., 2008; Buzanska et al., 2009;
Longley et al., 2003). Moreover, the statistically significant
difference between the IC50 values of dexamethasone and
acetaminophen in non-differentiated hNSCs and differentiated
glial cells suggests our platform is capable of detecting cell
type-dependent toxicities.
It is important, however, to point out that our expectation
was to find higher sensitivity of the proliferating hNSC
population to these compounds (Paquette et al., 2008;
Buzanska et al., 2009), since all of them have been reported
to exhibit antiproliferative activity (Breier et al., 2008;
Buzanska et al., 2009), and as such might be expected to
compromise cell division and perhaps induce differentiation
(Dietrich et al., 2006). This is particularly the case with
retinoic acid, as this compound is known to induce differen-
tiation in a wide variety of neural model systems and
embryonic stem cells (Martin-Ibanez et al., 2007; Rajasingh
and Bright, 2006). Nonetheless, precedence exists for studies
that show that toxicity is not necessarily limited to rapidly
dividing cells. For example, Noble and coworkersdemonstrated that non-dividing oligodendrocytes were as
sensitive as neural progenitors to chemotherapeutic agents
carmustine and cisplatin (Nutt et al., 2000). Moreover, the
authors showed that cell division by itself was insufficient to
confer vulnerability, as rapidly dividing hNSCs were more
resistant than progenitor cells.Conclusions
The characterization and safety assessment of drugs, drug
candidates, environmental chemicals, etc., require extensive
resources, particularly when animal studies are employed.
Neurotoxicity detection is particularly tedious, since regula-
tory authorities solely use in vivo methods for adult and
developmental neurotoxicity testing (Bal-Price et al., 2010).
The majority of commercial chemicals have not been
evaluated for developmental neurotoxicity. Thus, there is a
need to develop new in vitro techniques to predict which
compounds pose an increased threat to human health and
should therefore be prioritized for further screening and
evaluation.
In this work, we used a 3D cellular microarray platform
for high throughput analysis of hNSC differentiation and
toxicity screening. The hNSC microarray-based system
presents several advantages over more conventional ap-
proaches. First of all, it uses an immortalized hNSC line,
ReNcell VM, that proliferates readily and allows us to
generate a large number of cells of human origin. This cell
line has also been shown to differentiate into all three
neural subtypes (Donato et al., 2007), yielding mainly GFAP+
cells, followed by βIII-Tubulin+ cells and a small minority of
O1+ cells upon growth factor removal. In the same paper,
Donato et al. used a pre-aggregation step to yield mainly
dopaminergic neurons. Given this ability to produce both
cell types in abundance and their immortalized nature, the
ReNcell VM cell line offers a good source of neural cells and
as such could represent an appropriate model for the
developing brain, as well as for neuronal and glial lineages.
Moreover, the technology uses sensitive fluorescence-based
immunoassays and live/dead cell viability assays specifically
modified for the microarray format to screen relevant
endpoints, such as cytotoxicity/viability, self renewal/
differentiation, and changes in protein expression levels
that indicate shifts in important metabolic and signaling
pathways. All of this is done in a miniaturized 3D culture
platform that is expected to more closely mimic in vivo
46 L. Meli et al.environments and allows the screening of compounds in a
high throughput, highly parallel fashion.
Using this approach we showed that the ReNcell VM cell
line can be cultivated in 3D microarray alginate spots, and
preserve its proliferative progenitor state during on-chip
expansion, albeit with lower proliferation rates and viabilities
than those observed in conventional 2D culture platforms.
Additionally, through the use of an in-cell, on-chip immuno-
fluorescence assay to monitor levels of neurodevelopmental
markers, we demonstrated that the ReNcell VM cells initiate
differentiation into an astrocytic lineage following a standard
6 day differentiation protocol that consists of growth factor
removal. Moreover, the population of cells generated on-chip
has a similar marker prolife to cells that are cultured and
differentiated in 2D monolayers. Finally, we showed that our
platform can serve for high throughput predictive toxicology
screening of drugs and environmental chemicals by demon-
strating the cell type-dependent detection of adverse effects
of neurotoxic and antiproliferative compounds on cell prolif-
eration and viability, as well as the null effect of a non-toxic
compound at relevant concentrations. A better understanding
of the differential responses of human stem cells compared
with terminally differentiated cell types against chemicals is
vital to identify the toxic effects of such chemicals on the
human body and in specific organs, and to ensure retention of
healthy adult stem cell populations, which play a critical role
in tissue function and homeostasis. Future endeavors will
focus on the effects of potential neurotoxic compounds on
key signaling pathways involved in hNSC proliferation
(self-renewal) and differentiation; and efforts to obtain
pure populations of differentiated cells.Acknowledgments
The authors would like to thank Dr. Sandrine Lavenus and
Dr. Seok Joon Kwon for important discussions. This research
was supported by the National Institutes of Health (ES-020903).
HSCB acknowledges support from the PhD program on Bioengi-
neering: Cell Therapies and Regenerative Medicine (PD/00015/
2012) funded by the Portuguese Government (Fundação para a
Ciência e a Tecnologia).Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.04.004.References
Adams, J., Lammer, E.J., 1991. Relationship between dysmorphology
and neuropsychological function in children exposed to isotreti-
noin “in utero.”. In: Fujii, T., Boer, C.J. (Eds.), Functional
Neuroteratology of Short-term Exposure to Drugs. Teikyo Univer-
sity Press, Tokyo, pp. 59–70.
Andersen, M.E., Krewski, D., 2009. Toxicity testing in the 21st
century: bringing the vision to life. Toxicol. Sci. 107 (2),
324–330.
Ashton, R.S., et al., 2007. Scaffolds based on degradable alginate
hydrogels and poly(lactide-co-glycolide) microspheres for stem
cell culture. Biomaterials 28 (36), 5518–5525.Bal-Price, A.K., et al., 2010. Relevance of in vitro neurotoxicity
testing for regulatory requirements: challenges to be consid-
ered. Neurotoxicol. Teratol. 32 (1), 36–41.
Baud, O., 2004. Postnatal steroid treatment and brain development.
Arch. Dis. Child Fetal Neonatal Ed. 89, F96–F100.
Bogdahn, U., et al., 1987. Therapy of malignant brain tumors:
comparison of the in vitro activities of vidarabin-monophosphate,
BCNU and 5-fluorouracil. Acta Neurol. Scand. 75, 28–36.
Breier, J.M., et al., 2008. Development of a high-throughput
screening assay for chemical effects on proliferation and
viability of immortalized human neural progenitor cells. Toxicol.
Sci. 105 (1), 119–133.
Breier, J.M., et al., 2010. Neural progenitor cells as models for high-
throughput screens of developmental neurotoxicity: state of the
science. Neurotoxicol. Teratol. 32 (1), 4–15.
Buzanska, L., et al., 2009. A human stem cell-based model for
identifying adverse effects of organic and inorganic chemicals on
the developing nervous system. Stem Cells (Dayton, Ohio) 27 (10),
2591–2601.
Chauffert, B., Dimanche-Boitrel, M., 1998. New insights into the
kinetic resistance to anticancer agents. Cytotoxicology 27,
225–235.
Chayosumrit, M., Tuch, B., Sidhu, K., 2010. Alginate microcapsule
for propagation and directed differentiation of hESCs to
definitive endoderm. Biogeosciences 31, 505–514.
Cheng, K., Lai, Y., Kisaalita, W.S., 2008. Three-dimensional polymer
scaffolds for high throughput cell-based assay systems. Bioma-
terials 29, 2802–2812.
Clemedson, C., Kolman, A., Forsby, A., 2007. The integrated
acute systemic toxicity project (ACuteTox) for the optimisa-
tion and validation of alternative in vitro tests. Altern. Lab. Anim.
35, 33–38.
Costa, L.G., Fattori, V., Giordano, G., 2007. An in vitro approach to
assess the toxicity of certain food contaminants: methylmercury
and poly-chlorinated biphenyls. Toxicology 237, 65–76.
National Research Council, 2007. Toxicity Testing in the 21st
Century: A Vision and a Strategy. National Academies Press,
Washington, DC.
Dietrich, J., et al., 2006. CNS progenitor cells and oligodendrocytes
are targets of chemotherapeutic agents in vitro and in vivo. J.
Biol. 5 (22), 1–23.
Donato, R., et al., 2007. Differential development of neuronal
physiological responsiveness in two human neural stem cell lines.
BMC Neurosci. 8, 36.
Fernandes, T.G., et al., 2008. On-chip cell-based microarray
immunofluorescence assay for high-throughput analysis of target
proteins. Anal. Chem. 80 (17), 6633–6639.
Fernandes, T.G., et al., 2009. High-throughput cellular microarray
platforms: applications in drug discovery, toxicology and stem
cell research. Trends Biotechnol. 27 (6), 342–349.
Krencik, R., et al., 2011. Specification of transplantable astroglial
subtypes from human pluripotent stem cells. Nat. Biotechnol. 29
(6), 528–534.
Laustriat, D., Gide, J., Peschanski, M., 2010. Human pluripotent
stem cells in drug discovery and predictive toxicology. Biochem.
Soc. Trans. 38 (4), 1051–1057.
Lee, M.-Y., et al., 2008. Three-dimensional cellular microarray for
high-throughput toxicology assays. Proc. Natl. Acad. Sci. U. S. A.
105 (1), 59–63.
Longley, D.B., Harkin, D.P., Johnston, P.G., 2003. 5-Fluorouracil:
mechanisms of action and clinical strategies. Nat. Rev. Cancer 3
(5), 330–338.
Martin-Ibanez, R., et al., 2007. Interplay of leukemia inhibitory
factor and retinoic acid on neural differentiation of mouse
embryonic stem cells. J. Neurosci. Res. 85, 286–2701.
Meli, L., et al., 2012. Influence of a three-dimensional, microarray
environment on human cell culture in drug screening systems.
Biomaterials 33 (35), 9087–9096.
473D cellular microarray platform for human neural stem cell differentiation and toxicologyMiljan, E.A., 2007. ReNcell Human Neural Progenitors: Renewable
and Consistent Supply of Human Functional Neurons. Millipore
Technical Publications.
Nutt, C.L., et al., 2000. Differential expression of drug resistance
genes and chemosensitivity in glial cell lineages correlate with
differential response of oligodendrogliomas and astrocytomas to
chemotherapy. Cancer Res. 60, 4812–4818.
Paquette, J.A., et al., 2008. Assessment of the embryonic stem cell
test and application and use in the pharmaceutical industry.
Birth Defects Res B 83, 104–111.
Rajasingh, J., Bright, J.J., 2006. 15-Deoxy-delta12,14-prostaglanding
J2 regulates leukemia inhibitory factor signaling through JAK-STAT
pathway in mouse embryonic stem cells. Exp. Cell Res. 312,
2538–2546.Rieske, P., et al., 2007. A population of human brain parenchymal
cells express markers of glial, neuronal and early neural cells and
differentiate into cells of neuronal and glial lineages. Eur. J.
Neurosci. 25 (1), 31–37.
Saunders, J.B., Wright, N., Lewis, K.O., 1980. Predicting outcome of
paracetamol poisoning by using 14C-aminopyrine breath test. Br.
Med. J. 280, 279–280.
Trosko, J.E., Chang, C., 2010. Factors to consider in the use of stem
cells for pharmaceutic drug development and for chemical
safety assessment. Toxicology 270, 18–34.
Wang, L., Kisaalita, W.S., 2010. Characterization of micropatterned
nanofibrous scaffolds for neural network. J. Biomed. Mater. Res.
B Appl. Biomater. 94B, 238–249.
